share_log

Canaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $92

Canaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $92

Canaccord Genuity維持對globus medical的買入評級,將目標價提高至92美元
Benzinga ·  12/10 01:32  · 評級/大行評級

Canaccord Genuity analyst William Plovanic maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $85 to $92.

Canaccord Genuity的分析師William Plovanic維持對globus medical(紐交所:GMED)的買入評級,並將價格目標從85美元提高至92美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論